APA
Click to copy
Heyckendorf, J., van Leth, F., Avsar, K., Glattki, G., Günther, G., Kalsdorf, B., … Lange, C. (2018). Treatment responses in multidrug-resistant tuberculosis in Germany. The International Journal of Tuberculosis and Lung Disease.
Chicago/Turabian
Click to copy
Heyckendorf, J., F. van Leth, K. Avsar, G. Glattki, G. Günther, B. Kalsdorf, M. Müller, et al. “Treatment Responses in Multidrug-Resistant Tuberculosis in Germany.” The International Journal of Tuberculosis and Lung Disease (2018).
MLA
Click to copy
Heyckendorf, J., et al. “Treatment Responses in Multidrug-Resistant Tuberculosis in Germany.” The International Journal of Tuberculosis and Lung Disease, 2018.
BibTeX Click to copy
@article{j2018a,
title = {Treatment responses in multidrug-resistant tuberculosis in Germany.},
year = {2018},
journal = {The International Journal of Tuberculosis and Lung Disease},
author = {Heyckendorf, J. and van Leth, F. and Avsar, K. and Glattki, G. and Günther, G. and Kalsdorf, B. and Müller, M. and Olaru, I. and Rolling, T. and Salzer, H. and Schuhmann, M. and Terhalle, E. and Lange, C.}
}
BACKGROUND Excellent treatment outcomes have recently been reported for patients with multi/extensively drug-resistant tuberculosis (M/XDR-TB) in settings where optimal resources for individualised therapy are available.
OBJECTIVE To ascertain whether differences remain in treatment responses between patients with M/XDR-TB and those with non-M/XDR-TB.
METHOD Patients with TB were prospectively enrolled between March 2013 and March 2016 at five hospitals in Germany. Treatment was conducted following current guidelines and individualised on the basis of drug susceptibility testing. Two-month and 6-month sputum smear and sputum culture conversion rates were assessed. A clinical and radiological score were used to assess response to anti-tuberculosis treatment.
RESULTS Non-M/XDR-TB (n = 29) and M/XDR-TB (n = 46) patients showed similar rates of microbiological conversion: 2-month smear conversion rate, 90% vs. 78%; culture conversion rate, 67% vs. 61%; time to smear conversion, 19 days (IQR 10-32) vs. 31 days (IQR 14-56) (P = 0.066); time to culture conversion, 39 days (IQR 17-67) vs. 39 days (IQR 6-85) (P = 0.191). Both clinical and radiological scores decreased after the introduction of anti-tuberculosis treatment.
CONCLUSION There were no significant differences in scores between the two groups until 6 months of treatment. Under optimal clinical conditions, with the availability of novel diagnostics and a wide range of therapeutic options for individualised treatment, patients with M/XDR-TB achieved 6-month culture conversion rates that were compatible with those in patients with non-M/XDR-TB.